Bio Green Med Solution, Inc. (BGMS) 10-Year Financial Performance & Capital Metrics

BGMS • • Industrial / General

HealthcarePharmaceuticalsBiopharmaceutical R&DOncology Therapeutics

AboutA diversified company operating in both the fire protection and biopharmaceutical industries. It expanded its portfolio by acquiring Fitters Sdn. Bhd., a Malaysian fire protection products and services group. Focuses on advancing opportunities in biopharmaceutical research and fire safety solutions to create sustainable long-term shareholder value.Show more

Revenue $43K -89.8%
EBITDA -$12M +52.8%
Net Income -$11M +50.3%
EPS (Diluted) -501.60 +92.2%
Gross Margin 100%
EBITDA Margin -27902.33% -361.0%
Operating Margin -27916.28% -360.6%
Net Margin -26074.42% -385.5%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM9.46%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM59.5%

EPS CAGR

10Y-

5Y-

3Y-

TTM96.39%

ROCE

10Y Avg-107.1%

5Y Avg-107.1%

3Y Avg-167.63%

Latest-

Peer Comparison

Oncology Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
HCMHUTCHMED (China) Limited	2.63B	15.31	69.59	-24.8%	77.53%	37.59%	0.12
SHPHShuttle Pharmaceuticals Holdings, Inc.	2.85M	1.48	-0.00			-7.68%	1.65
BGMSBio Green Med Solution, Inc.	7.01M	1.43	-0.00	-89.76%	-67.15%	-76.65%
SBFMSunshine Biopharma, Inc.	5.99M	1.22	-0.17	44.75%	-17.35%	-24.55%	0.04
RNTXRein Therapeutics Inc.	30.49M	1.16	-0.33			-127.48%
CGEMCullinan Therapeutics, Inc.	629.75M	10.66	-3.43			-48.03%	0.00
ONCBeOne Medicines Ltd.	34.44B	338.29	-55.28	54.96%	1.38%	1.66%	0.32

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	420K	43K
Revenue Growth %	-	-	-	-	-0.9%
Cost of Goods Sold+	20K	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	-20K	0	0	420K	43K
Gross Margin %	-	-	-	1%	1%
Gross Profit Growth %	-	1%	-	-	-0.9%
Operating Expenses+	10.62M	22.39M	27.66M	25.87M	12.05M
OpEx % of Revenue	-	-	-	61.6%	280.16%
Selling, General & Admin	5.88M	7.46M	7.38M	6.72M	5.39M
SG&A % of Revenue	-	-	-	16%	125.4%
Research & Development	4.74M	14.93M	20.27M	19.16M	6.66M
R&D % of Revenue	-	-	-	45.61%	154.77%
Other Operating Expenses	0	0	0	0	0
Operating Income+	-10.64M	-22.39M	-27.66M	-25.45M	-12M
Operating Margin %	-	-	-	-60.6%	-279.16%
Operating Income Growth %	-	-1.11%	-0.24%	0.08%	0.53%
EBITDA+	-10.62M	-22.35M	-27.62M	-25.42M	-12M
EBITDA Margin %	-	-	-	-60.53%	-279.02%
EBITDA Growth %	-	-1.1%	-0.24%	0.08%	0.53%
D&A (Non-Cash Add-back)	20K	43K	32K	31K	6K
EBIT	-9.68M	-22.39M	-27.66M	-25.45M	-12M
Net Interest Income+	42K	16K	210K	266K	12K
Interest Income	42K	16K	210K	266K	12K
Interest Expense	0	0	0	0	0
Other Income/Expense	955K	204K	1.74M	-98K	10K
Pretax Income+	-9.68M	-22.18M	-25.91M	-25.55M	-11.99M
Pretax Margin %	-	-	-	-60.84%	-278.93%
Income Tax+	-1.24M	-3.73M	-4.72M	-3M	-782K
Effective Tax Rate %	0.87%	0.83%	0.82%	0.88%	0.93%
Net Income+	-8.45M	-18.46M	-21.2M	-22.55M	-11.21M
Net Margin %	-	-	-	-53.7%	-260.74%
Net Income Growth %	-	-1.19%	-0.15%	-0.06%	0.5%
Net Income (Continuing)	-8.45M	-18.46M	-21.2M	-22.55M	-11.21M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-12306.00	-7704.00	-6840.00	-6420.00	-501.60
EPS Growth %	-	0.37%	0.11%	0.06%	0.92%
EPS (Basic)	-12306.00	-7704.00	-6840.00	-6420.00	-501.60
Diluted Shares Outstanding	1.01K	2.48K	3.13K	3.54K	22.31K
Basic Shares Outstanding	1.01K	2.48K	3.13K	3.54K	22.31K
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	35.47M	40.94M	24.41M	7.44M	3.67M
Cash & Short-Term Investments	33.41M	36.56M	18.34M	3.38M	3.14M
Cash Only	33.41M	36.56M	18.34M	3.38M	3.14M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	1.31M	4.3M	5.64M	3.73M	237K
Days Sales Outstanding	-	-	-	3.24K	2.01K
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	66K	-498K	426K	341K	300K
Total Non-Current Assets+	1.33M	2.19M	3.64M	1.36M	419K
Property, Plant & Equipment	1.33M	94K	174K	102K	7K
Fixed Asset Turnover	-	-	-	4.12x	6.14x
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	2.1M	3.46M	1.26M	412K
Total Assets+	36.8M	43.14M	28.05M	8.8M	4.09M
Asset Turnover	-	-	-	0.05x	0.01x
Asset Growth %	-	0.17%	-0.35%	-0.69%	-0.54%
Total Current Liabilities+	2.49M	5.41M	7.51M	8.16M	6.27M
Accounts Payable	514K	2.12M	2.56M	3.54M	4.6M
Days Payables Outstanding	9.38K	-	-	-	-
Short-Term Debt	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	866K	753K	1.01M	380K	283K
Current Ratio	14.27x	7.56x	3.25x	0.91x	0.59x
Quick Ratio	14.27x	7.56x	3.25x	0.91x	0.59x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	1.06M	30K	106K	37K	0
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	1.06M	30K	106K	37K	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0
Total Liabilities	3.54M	5.44M	7.62M	8.2M	6.27M
Total Debt+	1.06M	30K	106K	37K	0
Net Debt	-32.35M	-36.53M	-18.24M	-3.34M	-3.14M
Debt / Equity	0.03x	0.00x	0.01x	0.06x	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-	-	-	-
Total Equity+	33.26M	37.69M	20.43M	607K	-2.17M
Equity Growth %	-	0.13%	-0.46%	-0.97%	-4.58%
Book Value per Share	32962.34	15204.92	6536.47	171.23	-97.43
Total Shareholders' Equity	33.26M	37.69M	20.43M	607K	-2.17M
Common Stock	6K	10K	4.5M	1K	9K
Retained Earnings	-366.07M	-384.53M	-405.73M	-428.28M	-439.49M
Treasury Stock	0	0	0	0	0
Accumulated OCI	-746K	-748K	-1.32M	-908K	-891K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.93M	-18.54M	-20.83M	-16.11M	-7.99M
Operating CF Margin %	-	-	-	-38.36%	-185.81%
Operating CF Growth %	-	-1.34%	-0.12%	0.23%	0.5%
Net Income	-8.45M	-18.46M	-21.2M	-22.55M	-11.21M
Depreciation & Amortization	20K	43K	32K	31K	6K
Stock-Based Compensation	430K	1.16M	1.51M	1.47M	592K
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	-63K	0	0	0	0
Working Capital Changes	124K	-1.28M	-1.17M	4.94M	2.62M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	0	3.02M	2.58M	296K	-1.81M
Cash from Investing+	-96K	-27K	-7K	-6K	0
Capital Expenditures	-96K	-27K	-7K	-6K	0
CapEx % of Revenue	-	-	-	0.01%	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	29.5M	21.74M	3M	848K	7.82M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	-201K	-201K	-201K	-201K	0
Share Repurchases	-	-	-	-	-
Other Financing	0	4.57M	0	0	1.61M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-8.03M	-18.57M	-20.83M	-16.12M	-7.99M
FCF Margin %	-	-	-	-38.38%	-185.81%
FCF Growth %	-	-1.31%	-0.12%	0.23%	0.5%
FCF per Share	-7958.37	-7489.71	-6664.75	-4546.69	-358.07
FCF Conversion (FCF/Net Income)	0.94x	1.00x	0.98x	0.71x	0.71x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	2K	2K	2K

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-25.39%	-52.03%	-72.94%	-214.4%	-
Return on Invested Capital (ROIC)	-876.59%	-1619.26%	-1235.38%	-	-
Gross Margin	-	-	-	100%	100%
Net Margin	-	-	-	-5370.24%	-26074.42%
Debt / Equity	0.03x	0.00x	0.01x	0.06x	-
FCF Conversion	0.94x	1.00x	0.98x	0.71x	0.71x
Revenue Growth	-	-	-	-	-89.76%

Frequently Asked Questions

Growth & Financials

Bio Green Med Solution, Inc. (BGMS) reported $0.1M in revenue for fiscal year 2024.

Bio Green Med Solution, Inc. (BGMS) saw revenue decline by 89.8% over the past year.

Bio Green Med Solution, Inc. (BGMS) reported a net loss of $5.4M for fiscal year 2024.

Dividend & Returns

Bio Green Med Solution, Inc. (BGMS) had negative free cash flow of $6.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener